North America Diabetes Care Devices Market Outlook to 2016 -





  Published: Nov-2010   

GlobalData’s new report, “North America Diabetes Care Devices Market Outlook to 2016” provides key market data on the North America Diabetes Care Devices market – United States and Canada. The report provides value (USD million) data for all the market categories – Glucose Monitoring, Insulin Delivery. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.   


Scope  

  •  Countries covered include United States and Canada.  
  • Market size and company share data for Diabetes Care Devices market categories – Glucose Monitoring, Insulin Delivery.  
  • Annualized market revenues (USD million) data for each of the market categories in each of the country. Data from 2002 to 2009, forecast forward for 7 years to 2016.  
  • 2009 company shares and distribution shares data for each of the market categories and countries.   
  • Global corporate-level profiles of key companies operating within the North America Diabetes Care Devices market.  
  • Key players covered include. LifeScan, Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Abbott Laboratories, Medtronic, Inc.,, Bayer HealthCare AG, Becton, Dickinson and Company, Novo Nordisk A/S, Sanofi-Aventis, Animas Corporation  

Reasons to Buy  

  •  Develop business strategies by identifying the key market categories and segments poised for strong growth.  
  • Develop market-entry and market expansion strategies.  
  • Design competition strategies by identifying who-stands-where in the North America Diabetes Care Devices competitive landscape.  
  • Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.  
  • What are the key distribution channels and what's the most preferred mode of product distribution – Identify, understand and capitalize 

 

1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 9
2 Introduction 10
2.1 What is This Report About? 10
3 Diabetes Care Devices in North America 11
3.1 Diabetes Care Devices Cross Country Comparison, Revenue ($m), 2002-2016 11
3.2 Diabetes Care Devices, North America, Overall Revenue ($m), 2002-2016 12
3.3 Diabetes Care Devices, North America, Category Volume (Units), 2002-2016 17
3.4 Diabetes Care Devices, North America, Company share (2008-2009) 22
4 Diabetes Care Devices In United States 24
4.1 Diabetes Care Devices, United States, Overall Revenue ($m), 2002-2016 24
4.2 Diabetes Care Devices, United States, Category Volume (Units), 2002-2016 30
4.3 Diabetes Care Devices, United States, Distribution Share (2008-2009) 35
4.3.1 Glucose Monitoring, United States, Distribution Share (2008-2009) 35
4.3.2 Insulin Delivery, United States, Distribution Share (2008-2009) 35
4.4 Diabetes Care Devices, United States, Company Share (2008-2009) 36
4.4.1 Diabetes Care Devices, United States, Company Share (2008-2009) 36
4.4.2 Glucose Monitoring, United States, Company Share (2008-2009) 38
4.4.3 Insulin Delivery, United States, Company Share (2008-2009) 40
5 Diabetes Care Devices In Canada 42
5.1 Diabetes Care Devices, Canada, Overall Revenue ($m), 2002-2016 42
5.2 Diabetes Care Devices, Canada, Category Volume (Units), 2002-2016 45
5.3 Diabetes Care Devices, Canada, Distribution Share (2008-2009) 49
5.3.1 Glucose Monitoring, Canada, Distribution Share (2008-2009) 49
5.3.2 Insulin Delivery, Canada, Distribution Share (2008-2009) 49
5.4 Diabetes Care Devices, Canada, Company Share (2008-2009) 50
5.4.1 Diabetes Care Devices, Canada, Company Share (2008-2009) 50
5.4.2 Glucose Monitoring, Canada, Company Share (2008-2009) 52
5.4.3 Insulin Delivery, Canada, Company Share (2008-2009) 54
6 Overview of Key Companies in North America Diabetes Care Devices Market 56
6.1 LifeScan, Inc. 56
6.1.1 Company Overview 56
6.1.2 Share in the North America Diabetes Care Devices Market 56
6.2 F. Hoffmann-La Roche Ltd. 57
6.2.1 Company Overview 57
6.2.2 Share in the North America Diabetes Care Devices Market 57
6.3 Eli Lilly and Company 58
6.3.1 Company Overview 58
6.3.2 Share in the North America Diabetes Care Devices Market 58
6.4 Abbott Laboratories 59
6.4.1 Company Overview 59
6.4.2 Share in the North America Diabetes Care Devices Market 59
6.5 Medtronic, Inc. 60
6.5.1 Company Overview 60
6.5.2 Share in the North America Diabetes Care Devices Market 60
6.6 Bayer HealthCare AG 61
6.6.1 Company Overview 61
6.6.2 Share in the North America Diabetes Care Devices Market 61
6.7 Becton, Dickinson and Company 62
6.7.1 Company Overview 62
6.8 Novo Nordisk A/S 62
6.8.1 Company Overview 62
6.9 Sanofi-Aventis 62
6.9.1 Company Overview 62
6.10 Animas Corporation 63
6.10.1 Company Overview 63
6.11 ARKRAY, Inc. 63
6.11.1 Company Overview 63
6.12 Smiths Medical 63
6.12.1 Company Overview 63
7 Diabetes Care Devices Market Pipeline Products 64
8 Financial Deals Landscape 67
8.1 Acquisition 67
8.1.1 PositiveID Completes Acquisition Of Easy Check Medical Diagnostics 67
8.1.2 Nipro Completes Acquisition Of Home Diagnostics 68
8.2 Partnerships 70
8.2.1 Voxiva Enters Into An Agreement With PositiveID 70
8.2.2 PharmaTech Solutions Enters Into Exclusive Distribution Agreement 71
8.2.3 Cellnovo Enters Into An Agreement With Home Diagnostics 72
8.2.4 AgaMatrix Enters Signs Agreement With Sanofi-Aventis 73
8.2.5 JDRF Enters Into An Agreement With Becton, Dickinson and Company 74
9 Recent Developments 75
9.1 Strategy and Business Planning 75
9.1.1 Nov 09, 2010: Medtronic Opens New Distribution Center In Elizabeth, New Jersey 75
9.1.2 Sep 14, 2010: i3 Expands Partnership with Lilly 75
9.1.3 Aug 18, 2010: T-Ray Announces Reorganization 75
9.1.4 Jun 03, 2010: Johnson & Johnson Highlights Growth Strategies For MD&D Segment 76
9.1.5 Feb 17, 2010: Greatbatch Medical Opens New Orthopaedic Design Center In Warsaw, Indiana 77
9.1.6 Jan 28, 2010: UltiMed Expanding De Smet Operations 78
9.1.7 Jan 13, 2010: JDRF Forms Partnership With Animas To Develop First-Generation Automated System For Managing Type 1 Diabetes 78
9.1.8 Jan 12, 2010: PositiveID To Expand Its HealthID Division With Diabetes Products 79
9.2 Legal and Regulatory 79
9.2.1 Aug 20, 2010: XTend Schedules Date For Mediation In Delaware Chancery Court 79
9.2.2 Aug 19, 2010: US Patent Office Rules Oculir Patent Invalid 80
9.2.3 Jul 27, 2010: Nova Biomedical's Diabetes Care Products Held Not To Infringe Roche's Claims 80
9.2.4 Jun 18, 2010: XTend Provides Update On Delaware Lawsuit 81
9.2.5 May 19, 2010: XTend Medical Files Complaint In Delaware Chancery Court 82
9.2.6 Apr 06, 2010: Generex Launches Lawsuit Against TheStreet.com And Feuerstein 82
9.2.7 Dec 14, 2009: Lawsuit Filed Over Recall Of Quick-Set Infusions Sets For MiniMed Paradigm Insulin Pumps 82
9.2.8 Dec 09, 2009: Med Graph Files Patent Lawsuit Against Medtronic 83
9.3 Government and Public Interest 83
9.3.1 Oct 13, 2010: AACE Releases Consensus Statement For Continuous Glucose Monitoring 83
9.3.2 Oct 08, 2010: Senator Grassley Questions VA Official's Relationship With Medtronic 84
9.3.3 Sep 23, 2010: Blood Glucose Meter Along With Diabetes Education Helps Control Blood Sugar In Diabetics, Study Finds 84
9.3.4 Sep 01, 2010: CDC Advises Fingerstick Devices Not To Be Used For More Than One Person 85
9.3.5 Aug 23, 2010: Researchers Find Technology That May Make Lifesaving Implanted Devices Last Longer 86
9.3.6 Aug 16, 2010: JDRF Launches Research Program To Accelerate Delivery Of Faster Acting Insulin 87
9.3.7 Aug 13, 2010: 2010 Medical Innovation Summit To Showcase Innovations In Treating Obesity And Diabetes 88
9.3.8 Aug 12, 2010: New Study Suggests Artery Compressing Base of Brain Is Factor In Type 2 Diabetes Mellitus: AGH Neurosurgical Team 89
9.3.9 Aug 09, 2010: New Device For Patients To Monitor Blood Glucose Levels: MIT Spectroscopy Laboratory 90
9.3.10 Jul 28, 2010: University Of California, San Diego And GlySens Develop Implantable Glucose Sensor That Works For More Than One Year 91
9.3.11 Jul 20, 2010: Abbott Diabetes Care Receives FDA Warning Letter 93
9.3.12 May 11, 2010: Experimental Sensor Could Help Diabetics Monitor Blood Sugar Without Pricking Their Fingers 93
9.3.13 Apr 16, 2010: Hospira Receives FDA Warning Letter For Two North Carolina Facilities 93
9.3.14 Apr 15, 2010: Monofilament Exam Forecasts Long-Term Risk For Diabetic Neuropathy 94
9.3.15 Apr 14, 2010: BU Researchers Develop Artificial Pancreas, Which Succeeds In Maintaining Near-Normal Glucose Levels 95
9.3.16 Apr 14, 2010: Novel Artificial Pancreas Successfully Controls Blood Sugar More Than 24 Hours: Boston University 96
9.3.17 Apr 12, 2010: Baylor University Researchers Develop Portable Non-Invasive Blood Glucose Monitor 98
9.3.18 Mar 05, 2010: FDA Panel Concludes Improper Use Of Insulin Pumps By Patients Poses Greater As Compared To The Problems Caused Due To Defects In The Device 98
9.3.19 Mar 04, 2010: FDA Panel To Examine Insulin Pump Problems 99
9.3.20 Jan 21, 2010: New Study: Changes In Position Of Conventional Insulin Pumps Can Cause Fluctuations In Insulin Delivery Rates 99
9.3.21 Jan 15, 2010: FDA To Discuss The Clinical Accuracy Requirements Of Blood Glucose Meters 100
9.4 Product News 100
9.4.1 Jun 29, 2010: Medtronic Announces STAR 3 Trial Results Confirming MiniMed Paradigm REAL-Time System Achieves Better Glucose Control Than Daily Insulin Injections In Diabetic Patients 100
9.4.2 Jun 25, 2010: Medtronic Begins Enrollment In ASPIRE Pivotal Study Of MiniMed Paradigm x54 System 101
9.4.3 Mar 17, 2010: Medtronic Announces FDA Approval Of MiniMed Paradigm REAL-Time Revel System 102
10 Appendix 103
10.1 Definitions of Markets Covered in the Report 104
10.1.1 Diabetes Care Devices 104
10.2 Research Methodology 105
10.3 Secondary Research 105
10.4 Primary Research 106
10.5 Models 106
10.6 Forecasts 107
10.7 Expert Panels 107
10.8 GlobalData Consulting 107
10.9 Currency Conversion 108
10.10 Contact Us 108
10.11 Disclaimer 108